Analyst Interview: As Cancer Immunotherapy Turns 125, WBB Securities’ Steve Brozak Ponders What Investors Can Expect from Biotech Next
Posted: May 27th, 2015In: Opinions & FeaturesSteve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do.
Read More about Analyst Interview: As Cancer Immunotherapy Turns 125, WBB Securities’ Steve Brozak Ponders What Investors Can Expect from Biotech NextWBB Securities Acts as Financial Advisor on $60 Million Loan for Navidea Biopharmaceuticals
Posted: May 11th, 2015In: Press ReleasesWBB Securities acted as financial advisor to Navidea Biopharmaceuticals regarding a term loan with CRG (formerly Capital Royalty LP). Under the terms of the agreement, CRG will provide Navidea with initial funding of $50[...]
Read More about WBB Securities Acts as Financial Advisor on $60 Million Loan for Navidea BiopharmaceuticalsWBB Securities Acts as Placement Agent for up to $25 Million in Equity Financing for Cytori Therapeutics
Posted: May 8th, 2015In: Press ReleasesWBB Securities acted as placement agent to a transaction for Cytori Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing autologous cell therapies from adipose tissue to treat a variety of medical conditions.
Read More about WBB Securities Acts as Placement Agent for up to $25 Million in Equity Financing for Cytori TherapeuticsWBB Securities Co-Manages $25 Million Public Offering for TetraLogic
Posted: May 1st, 2015In: UncategorizedWBB Securities is acting as co-manager to a transaction for TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology.
Read More about WBB Securities Co-Manages $25 Million Public Offering for TetraLogic